Skip to content
Medical Health Aged Care

Burjeel Holdings Prices First MENA Healthcare Sukuk Since 2018, 3.2x Oversubscribed

Burjeel Holdings 2 mins read
ABU DHABI, United Arab Emirates--BUSINESS WIRE--

Burjeel Holdings, a leading super-specialty healthcare group in the GCC listed on the Abu Dhabi Securities Exchange, priced its inaugural USD 500 million Regulation S 5-year senior unsecured Sukuk offering due 2031 under its newly established USD 1.5 billion Senior Unsecured Sukuk Programme.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625449702/en/

Burjeel Holdings’ inaugural Sukuk was priced at a 7.000 % profit rate and a yield of 7.125% (Photo: AETOSWire)

Burjeel Holdings’ inaugural Sukuk was priced at a 7.000 % profit rate and a yield of 7.125% (Photo: AETOSWire)

The offering attracted significant demand from high-quality international and regional investors, with the orderbook peaking at USD 1.6 billion, representing 3.2x oversubscription. The strength of the orderbook enabled Burjeel to tighten pricing from initial price thoughts in the mid-7% area, with the Sukuk priced at a 7.000% profit rate and a yield of 7.125%, representing the lowest 5-year yield by a GCC-based private non-investment grade corporate issuer since 2020.

International investors accounted for 61% of the final allocation, led by the UK (34%) and US Offshore investors (24%), alongside strong GCC participation of 39%, highlighting global confidence in Burjeel and the UAE's capital markets.

Rated BB+ by S&P Global Ratings and Ba2 by Moody's Ratings, the transaction marks the first Sukuk offering from a MENA healthcare provider since 2018 and the first UAE corporate offering since recent regional developments.

Net proceeds will be used in line with the offering documents, including refinancing existing debt and supporting the Group's strategic priorities, strengthening Burjeel's financial flexibility and long-term capital structure.

Dr. Shamsheer Vayalil, Chairman and CEO, said:The strong demand for our inaugural Sukuk reflects investor recognition of Burjeel’s strategy, credit fundamentals, and ability to deliver sustainable growth. With strong international participation, this transaction broadens our access to global capital markets and provides greater financial flexibility to advance our strategic priorities, including investments in advanced clinical care, research, medical education, and AI-enabled healthcare innovation, as we work to power the next generation of healthcare.

The Sukuk is admitted to trading on the London Stock Exchange’s International Securities Market, subject to customary closing conditions.

Citi, Emirates NBD Capital and FAB acted as Joint Global Coordinators. Emirates NBD Capital and FAB also acted as Sukuk Structuring Agents. ADCB, ADIB, Dubai Islamic Bank, RAKBANK and Sharjah Islamic Bank acted as Joint Lead Managers and Bookrunners.

About Burjeel Holdings

Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia.

*Source: AETOSWire


Contact details:

Salam Shehady
[email protected]

Media

More from this category

  • Medical Health Aged Care
  • 26/06/2026
  • 02:02
Imagion Biosystems, Ltd.

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

MELBOURNE, Australia–BUSINESS WIRE– Imagion Biosystems, Ltd. (ASX: IBX) announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following the FDA’s…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 25/06/2026
  • 09:35
INOVIQ Limited (ASX:IIQ)

POSITIVE CAR-EXOSOME IN VITRO TUMOUR KILLING DEMONSTRATED IN OVARIAN CANCER CELLS

Melbourne, Australia, 25 June 2026: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company), a biotechnology company developing next-generation exosome-based diagnostics and therapeutics to improve cancer…

  • Contains:
  • General News, Medical Health Aged Care
  • 25/06/2026
  • 07:02
Thoracic Society of Australia and New Zealand (TSANZ) and Monash University

New national guidance to support doctors assessing workers exposed to silica dust

Workers at risk of serious lung disease after harmful silica dust exposure can benefit from updated national guidelines that will help GPs identify those at risk and refer them for appropriate diagnostic testing and treatment. While Australia’s world-leading ban on engineered stone in 2024 will save countless workers from silica-associated disease, including silicosis and other occupational respiratory diseases, additional work was required to ensure the health system could adequately support those previously exposed. The National guidance for doctors assessing workers exposed to respirable crystalline silica dust 2026 was developed through an Australian Government-funded project led by the Thoracic Society of…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.